MedTrace Logo

Impact of Clinical Evident Portal Hypertension on HCC With TACE (CHANCE-CHESS 2301)

NCT05703750 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 228

Last updated 2023-05-31

No results posted yet for this study

Summary

The purpose of this study is to discuss the prognostic value of CEPH among HCC patients underwent TACE treatment, its impact on overall survival, and try to stratify patient cohorts for a better treatment strategy.

Conditions

Interventions

PROCEDURE

TACE ± Systemic therapy

TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE); Systemic therapy: PD-1/PD-L1 inhibitors, VEGF-TKI/bevacizumab, PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, radiotherapy or chemotherapy.

Sponsors & Collaborators

  • Zhongda Hospital

    lead OTHER

Principal Investigators

  • Gao-Jun Teng, M.D. · Zhongda hospital, Southeast university, Nanjing, China

  • Xiaolong Qi, M.D. · Zhongda hospital, Southeast university, Nanjing, China

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-04
Primary Completion
2023-06-30
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05703750 on ClinicalTrials.gov